v3.20.4
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (82,169) $ (32,968)
Reconciliation of net loss to net cash used in operating activities    
Depreciation and amortization 188 156
Stock-based compensation expense 14,611 3,142
Changes in operating assets and liabilities:    
Prepaid expenses, other assets and right of use assets (2,013) (1,190)
Accounts payable, accrued expenses, lease liabilities and other liabilities 3,033 3,759
Net cash used in operating activities (66,350) (27,101)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment and leasehold improvements (316) (870)
Net cash used in investing activities (316) (870)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock, net of issuance costs 255,785 17,810
Purchase and cancellation of shares from BioXcel Corporation (9,024)  
Exercise of options 598 22
Net cash provided by financing activities 247,359 17,832
Net increase (decrease) in cash and cash equivalents 180,693 (10,139)
Cash and cash equivalents, beginning of the period 32,426 42,565
Cash and cash equivalents, end of the period 213,119 32,426
Supplemental cash flow information:    
Interest paid 27 62
Purchases of equipment and leasehold improvements in accounts payable and accrued expense 104  
Operating right of use lease assets obtained in exchange for operating lease liabilities $ 606  
Operating lease right of use asset and liability (non-cash adoption balances)   $ 1,308

Source